Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Cancers|May 27, 2026
Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) ProjectElisabetta Abruzzese, Monica Crugnola, Luca Garuffo, et al.
Leukemia Research|July 23, 2014
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survivalMassimo Breccia, Luigiana Luciano, Roberto Latagliata, et al.
American Journal of Hematology|July 5, 2017
ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systemsRena Buckstein, Enrico Balleari, Richard Wells, et al.
British Journal of Haematology|November 13, 2024
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndromeCarmelo Gurnari, Elisa Galossi, Eleonora Lumia, et al.
Cancers|May 14, 2025
Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and CaregiversElena Crisà, Daniela Cilloni, Marta Riva, et al.
Cancer|June 24, 2023
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CMLMario Tiribelli, Roberto Latagliata, Massimo Breccia, et al.
Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
American Journal of Hematology|December 18, 2023
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohortCarmelo Gurnari, Maria Rosaria Pascale, Antonio Vitale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Esther Natalie Oliva, Marta Riva, Pasquale Niscola, et al.
Pageof 5